RxDoctor Payments Data

Patalam Sriharsha, MD

Geriatric Psychiatry · Hazleton, PANPI 1154377562

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 59.6% of the total. Reporting peaked in 2019 at $308 and has fallen 94.1% since, to $18 in 2024.

$511in general payments, 2019–2025

Across 34 payments — averaging $15.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$305
  • AbbVie$79
  • Neurocrine Biosciences, Inc.$54
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$31
  • Otsuka America Pharmaceutical, Inc.$19
  • Teva Pharmaceuticals USA, Inc.$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$511100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$511 in reported general payments places this provider in the 70th percentile of 31 geriatric psychiatry providers in Pennsylvania.

See all geriatric psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,811
Medicare patients
114
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate51$121,880
Abilify MaintenaAripiprazole36$104,142
Clozapine124$12,558
Olanzapine268$11,901
Aripiprazole69$8,543
Risperidone ErRisperidone Microspheres11$7,516
Lurasidone Hcl12$4,954
Divalproex Sodium ErDivalproex Sodium147$4,562
Quetiapine Fumarate148$4,264
VyvanseLisdexamfetamine Dimesylate11$4,178
Risperidone193$4,088
Ziprasidone Hcl113$3,418
LoxapineLoxapine Succinate39$2,852
Lorazepam246$2,489
Benztropine Mesylate203$2,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$305$121,88051 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$19$104,14236 claims
Teva Pharmaceuticals USA, Inc.Loxapine$13$2,85239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 31 geriatric psychiatry providers in Pennsylvania.

Other geriatric psychiatry in Hazleton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →